25 mg) each administered twice daily in individuals with OIC.
‘The addition of the once-daily dosing study will expand our understanding of the efficacy, safety and tolerability of ADL5945, and the successful completion of the Stage 2 system should enable us to choose a dosage for pivotal confirmatory research,’ stated Michael R. Dougherty, President and Chief Executive Officer. ‘We anticipate reporting results from these research in the summertime of 2011 and moving the program forward into pivotal studies in early 2012.’.. Adolor initiates second ADL5945 Phase 2 research in opioid-induced constipation Adolor Corporation today announced that it’s initiating a second Phase 2 research of ADL5945 in chronic non-cancer pain individuals experiencing opioid-induced constipation .10 mg and 0.25 mg) each administered twice daily in individuals with OIC.We anticipate the technological discoveries that will result from this collaboration.’.
Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions Aclaris Therapeutics, Inc. Today announced excellent results from a Phase 2 scientific trial of the Organization's lead medication, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses , one of the most common types of epidermis tumors. While benign, many patients elect to have SK treated either as the lesions have grown to be irritated or are cosmetically concerning.